Necitumumab - Eli Lilly

Drug Profile

Necitumumab - Eli Lilly

Alternative Names: IMC-11F8; LY 3012211; Portrazza

Latest Information Update: 03 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ImClone Systems
  • Developer Eli Lilly
  • Class Antineoplastics; Fab fragments; Monoclonal antibodies
  • Mechanism of Action Epidermal growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • Phase II Solid tumours
  • No development reported Colorectal cancer

Most Recent Events

  • 05 Jun 2018 Safety and efficacy data from a phase I/II trial in Non-small cell lung cancer presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
  • 17 Apr 2018 Pharmacodynamics data from a preclinical trial in Non-small cell lung cancer presented at the 109th Annual Meeting of the American Association for Cancer Research (AACR-2018)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours in Japan (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top